| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
|
|
|||||||||
|
|
Oncology-Clinical Diagnosis: Hematologic TumorsHematology Malignancy |
1 Clinical Radiology, Kyushu University, Fukuoka, Japan
1425
Objectives: The purpose of this study was to address the role of FDG-PET for the detection and diagnosis of the extranodal lesions in patients with malignant lymphoma.
Methods: Sixty-seven patients (40 males, 27 females) were analyzed in this study. Their ages ranged from 7 to 91 years (mean 60 ± 16 years). Five patients had Hodgkin’s disease, and 62 had non-Hodgkin’s lymphoma. The clinical staging of each patient was determined based on the Ann Arbor system: Stage I, 24: Stage II, 14: Stage III, 11: Stage IV, 18. Contrast-enhanced CT, including extranodal lesions, and FDG-PET were performed prior to any treatments. The ability of CT with FDG-PET to diagnose extranodal lesions was retrospectively compared to that of CT without FDG-PET.
Results: Finally, 115 lesions were diagnosed as extranodal malignant lymphoma. CT without FDG-PET detected 72 of 115 lesions (62.6%), while CT with FDG-PET found 89 lesions (77.4%). Extranodal lesions that FDG-PET additionally detected were in the stomach (11), bone (2), skin (2), bone marrow (1), and pharynx (1). Among gastric malignant lymphomas, the detectability of diffuse large B cell lymphoma was increased by the addition of FDG-PET findings. On the other hand, other types of gastric lymphoma and bone marrow involvement were hardly detected by either CT with or CT without FDG-PET. Five patients (7.5%) were accurately upstaged by adding the FDG-PET findings. Extranodal lesions were correctly diagnosed in 2 of these patients by FDG-PET.
Conclusions: FDG-PET provides more information about extranodal malignant lymphoma lesions than do CT findings alone. Greater diagnostic accuracy can be obtained by adding FDG-PET findings to CT.
| ||||||||||||||||||||||||||||||||||||||
